P11. Efficacy and safety of erlotinib in advanced squamous cell lung cancer

BACKGROUND: Erlotinib is epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor which showed efficacy and tolerability in patients with advanced non-small cell lung cancer (NSCLC), especially in group of patients which harbor activating mutations in EGFR. AIM: To determine safety and effi...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Transl Lung Cancer Res
Main Authors: Jakopovic, Marko, Cucevic, Branka, Plestina, Sanja, Kukulj, Suzana, Roglic, Mihovil, Smojver-Jezek, Silvana, Korsic, Marta, Redzepi, Gzim, Samarzija, Miroslav
Format: Artigo
Jezik:Inglês
Izdano: Pioneer Bioscience Publishing Company 2014
Teme:
CELCC 2014 Abstracts
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4367745/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2014.AB023
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki